Close Menu

Yourgene

The company said the revenue growth was driven by growing international demand for its noninvasive prenatal testing products and services.

The company had a profit of £3.4 million, or £0.01 per share, for the year compared to a loss of £9.6 million, or £0.03 per share, the previous year.

Elucigene has been developing in vitro diagnostics for oncology and reproductive health, including tests for cystic fibrosis screening and prenatal fetal aneuploidy screening.

The company said its higher revenues were due in part to international performance including continued penetration of Middle Eastern and Asian markets.

Under the terms of the agreement, Yourgene will offer its NIPT products on Thermo's NGS instruments in Southeast Asia and pay off its debts to Thermo.

The company, which changed its name from Premaitha Health last month, saw a 73 percent increase in testing volumes during the first half of fiscal year 2018.

A brief recap of Genetics/Genomics news the week of Oct 5, 2018: OncoDNA, Interpace Diagnostics, B. Braun Melsungen & CeGat, and Premaitha

The placing and subscription shares that are part of the offering are expected to start trading on the AIM market of the London Stock Exchange later this month.

Pages

In PLOS this week: preconception carrier screening program results, comparative genomics-based analysis of Elizabethkingia meningoseptica, and more.

Canadian regulators are beginning to share information from new drug studies, Undark reports.

In a column at the Dallas Morning News, the Stanley Medical Research Institute's E. Fuller Torrey says the Human Genome Project hasn't delivered on promised results.

Researchers explore a possible genetic cause for some cases of sudden infant death syndrome, KOMO News reports.